Evidence map›Paper›PMID 36334155›Full record

ArticleJournal of cancer research and clinical oncology2023

A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.

M Maßmann, J Treckmann, P Markus, B Schumacher, D Albers, S Ting, B Mende, J Roehrle, I Virchow, V Rosery and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

M MaßmannWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
J TreckmannWest German Cancer Center, Department of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany.
P MarkusDepartment of General Surgery and Traumatology, Elisabeth Hospital Essen, Essen, Germany.
B SchumacherDepartment of Gastroenterology, Elisabeth Hospital Essen, Essen, Germany.
D AlbersDepartment of Gastroenterology, Elisabeth Hospital Essen, Essen, Germany.
S TingWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
B MendeCentral Pharmacy, University Hospital Essen, Essen, Germany.
J RoehrleWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
I VirchowWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
V RoseryWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
K LaueWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
G ZaunWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
K KostbadeWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
M PogorzelskiWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
K W SchmidWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
H BabaWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
J T SivekeWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
A PaulWest German Cancer Center, Department of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany.
H U SchildhausWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
M SchulerWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
M Wiesweg *West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
S Kasper *West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany. stefan.kasper-virchow@uk-essen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSystemic-inflammatory response parameters (SIR) are known prognostic markers in different tumour entities, but have not been evaluated in patients with iCCA treated with systemic chemotherapy. Therefore, we evaluated the impact of different SIR markers on the clinical course of patients with advanced iCCA treated at our center.

methodsSIR markers were retrospectively evaluated in 219 patients with iCCA at the West-German-Cancer-Center Essen from 2014 to 2019. Markers included neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), CRP, and the modified Glasgow-Prognostic-Score (mGPS), which were correlated with clinico-pathological findings, response to chemotherapy (ORR), progression-free (PFS) and overall survival (OS) using Kaplan-Meier analyses, and Cox proportional models.

resultsMedian overall survival (OS) of the entire cohort was 14.8 months (95% CI 11.2-24.4). Median disease-free survival (DFS) in 81 patients undergoing resection was 12.3 months (95% CI 9.7-23.1). The median OS from start of palliative CTX (OS

conclusionsInflammatory markers associate with inferior survival outcomes in patients with iCCA. A simple SIS may guide treatment decisions in patients treated with systemic chemotherapy.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaBile Ducts, IntrahepaticHumansInflammationLymphocytesPrognosisRetrospective StudiesAdvanced diseaseChemotherapyInflammationIntrahepatic cholangiocellular carcinomaPrognosisSystemic-inflammatory response parameters

Identifiers

PMID36334155
PMCPMC10349723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.